CAS: 1374248-81-3; (S)-N-((3S,5S,6R)-6-Methyl-2-Oxo-1-(2,2,2-Trifluoroethyl)-5-(2,3,6-Trifluorophenyl)Piperidin-3-yl)-2'-Oxo-1',2',5,7-Tetrahydrospiro[cyclopenta[b]Pyridine-6,3'-Pyrrolo[2,3-B]Pyridine]-3-Carboxamide

结构式图片

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-12240808-B2
    优先权日:2021-05-28
    标 题 :Process for the synthesis of calebin-a and its intermediates
    发明人:MAJEED MUHAMMED; NAGABHUSHANAM KALYANAM; MUTHUKAMAN NAGARAJAN; NAIDU PENTAKOTA PARADESI
    权利人:MAJEED MUHAMMED; NAGABHUSHANAM KALYANAM; MUTHUKAMAN NAGARAJAN; NAIDU PENTAKOTA PARADESI
    摘要:The invention discloses novel intermediates in the synthesis of Calebin A represented by formula 3. The invention also covers processes for the synthesis of Calebin-A and its analogs using compounds of formula 3.

    专利号:US-6417290-B1
    优先权日:2001-01-29
    标题:Synthesis of energetic polyester thermoplastic homopolymers and energetic thermoplastic elastomers formed therefrom
    发明人:AMPLEMAN GUY; BROCHU SYLVIE
    权利人:DEPT OF NAT DEFENCE
    摘要:Polymerization of α-bromomethyl-α-methyl-β-propiolactone (BMMPL) or α-chloromethyl-α-methyl-β-propiolactone (CMMPL) yielded thermoplastic homopolymers that upon azidation led to a novel energetic thermoplastic polyester: poly(α-azidomethyl-α-methyl-β-propiolactone) (PAMMPL). An energetic copolyether-ester thermoplastic elastomer was prepared by using glycidyl azide polymer, a dihydroxyl terminated energetic polymer, as a macroinitiator for the polymerization of BMMPL or CMMPL. The azidation of the resulting copolyether-ester yielded an energetic thermoplastic elastomer that melted at between 80° C. and 85° C. Polymerization of α-dibromomethyl-β-propiolactone (DBMPL) resulted in a polymer which upon azidation yielded a new energetic polymer that can be used as a binder or into an energetic thermoplastic elastomer synthesis.

    专利号:US-11401273-B2
    优先权日:2018-11-20
    标题:Asymmetric synthesis of Azaspiro compounds
    发明人:LELETI RAJENDER REDDY; WAMAN YOGESH; KALLURE PRIYA; BEGUM ZUBEDA; DIVYA THUMBAN; NALIVELA KUMARA SWAMY; VIJAY SAURABH; PARIKH PARANJAY; KOTTURI SHARADSRIKAR; PATEL CHIRAG; NAYAK KRISHNA; BAHAROONI KASIMRAZA; ZALAVADIYA VINKAL
    权利人:PIRAMAL PHARMA LTD
    摘要:The present invention relates to an improved asymmetric synthesis of azaspiro or diazaspiro compound (hereafter referred to as the compound 5, (5A) or (5N)) or their pharmaceutically acceptable salts and derivatives; through the formation of intermediate compounds 4, (4A) or (4N) respectively. The process comprises an unusual substrate specific highly diastereoselective as well as enantio-enriched 1-substituted 2-azaspiro[3.3]heptane or 1-substituted 2-diazaspiro[3.3]heptane compounds with high diastereoselectivity by addition of a cyclobutane carboxylate anion to a Davis-Ellman's imine, followed by reduction and cyclisation resulting in the selective formation of azaspiro or diazaspiro intermediate compound 4, (4A) or (4N); which on subsequently removing the sulfinyl group provides corresponding azaspiro or diazaspiro compound 5, (5A) or (5N) respectively.

    专利号:US-10647655-B2
    优先权日:2016-09-02
    标题:Method for the synthesis of permethrin
    发明人:PULLAGURLA MANIK REDDY; NANDA KUMAR MECHERIL VALSAN; VELIGETLA MADHUSUDHANA RAO; RANGISETTY JAGADEESH BABU
    权利人:BIOPHORE INDIA PHARMACEUTICALS PVT LTD
    摘要:An improved method for the synthesis of substantially pure Permethrin having purity greater than 99.5% by Gas Chromatography provided. The embodiments also relates to a purification process of Permethrin by recrystallization from methanol-water mixture.

    专利号:US-9611255-B2
    优先权日:2015-06-10
    标题 :Process for total synthesis of flavonoid compounds and isomers thereof
    发明人:RAO BATCHU VENKATESWARA; LINGAMURTHY MACHA; RAJU Gurrapu; SARMA VANKA UMAMAHESWARA
    权利人:COUNCIL SCIENT IND RES; COUNCIL SCIENT IND RES
    摘要:The present invention relates to the a process for total synthesis of flavonoid compounds of general formula I and isomers thereof n nwherein R 1 and R 2 is OH; R 3 â•?H orn n n n n n n n n n n The present invention particularly relates to the process for preparation and separation of (2S,3S)-taxifolin-6-C-β-D-glucopyranoside (ulmoside A), (2R,3R)-taxifolin-6-C-β-D-glucopyranoside and taxifolin.

    专利号:US-5338488-A
    优先权日:1992-09-10
    标 题:Process for the production of synthesis gas by oxidative converson of methane (or natural gas) using composite catalyst containing transitional and alkine earth metal oxides
    发明人:CHOUDHARY VASANT R; RAJPUT AMARJEET M; SANSARE SUBHASH D; PRABHAKAR BATHULA; MAMMAN AJIT S
    权利人:COUNCIL OF SCIENT RESEARCH
    摘要:The invention relates to a process for the production of synthesis gas by oxidative conversion of methane using composite catalysts having the formula: TmAOn, wherein T is a transition metal or metals, m is the T/A mole ratio and is from 0.01 to 100, A is an alkaline earth metal or metals, O is oxygen and n is the number of oxygen atoms needed to form a catalyst composite wherein each element of the composite has a complete set of valence electrons. In a preferred embodiment, the process includes passing a gas containing methane and oxygen over the composite catalyst in a fixed bed reactor at a pressure in the range of 0.5-50 atm, and at a temperature in the range of 200 DEG -1000 DEG C., and recovering the synthesis gas.
    江苏科本药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.cobenpharm.com
    企业联系电话:0571-28021577;28021578;88278597👤
    📞江苏科本药业有限公司 ⚠️参考联系方式
    联系人:王倩
    电话:0571-28021577;28021578;88278597
    手机:13958139292
    传真:0571-28021579
    邮箱:coben@coben.sina.net
    通信地址: 江苏省启东滨江精细化工园区上海路168号
    邮编: 310004
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江苏省启东滨江精细化工园区上海路168号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    苏州富士莱医药股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.fuslai.com
    企业联系电话:0512-52838773;52838772👤
    📞苏州富士莱医药股份有限公司 ⚠️参考联系方式
    联系人:陈健
    电话:0512-52838773;52838772

    传真:0512-52831795
    邮箱:sales@fuslai.com
    通信地址: 江苏常熟新材料产业园海旺路16号
    邮编: 215522
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江苏常熟新材料产业园海旺路16号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    常州制药厂有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.czzyc.com
    企业联系电话:0519-88256855;81592036;81592036👤
    📞常州制药厂有限公司 ⚠️参考联系方式
    联系人:丁晨
    电话:0519-88256855;81592036;81592036
    手机:17301516125
    传真:0519-88828412;88256855
    邮箱:wxt@czpharma.com,dengxian@czpharma.com,zhangxinchun@czpharma.com
    通信地址: 江苏省常州市劳动东路518号
    邮编:
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江苏省常州市劳动东路518号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Diener HC, Grans J, Reuter U. Drugs for Migraine Prophylaxis. Dtsch Arztebl Int. 2026 Mar 6;(Forthcoming):arztebl.m2025.0234. doi: 10.3238/arztebl.m2025.0234. Epub ahead of print.
    16:1708226. doi: 10.3389/fphar.2025.1708226.
    3: Ladhwani NK, Bai P, Lal R, Shah AM, Bai S, Ahmed GU, Zameer R, Shaikh VF, Hyder A, Ali S, Beg MH, Adeeb M, Tesfaye M. The role of Atogepant in migraine prevention: a systematic review and meta-analysis. BMC Neurol. 2025 Sep 2;25(1):375. doi: 10.1186/s12883-025-04394-z.

    合成参考文献


    摘要:Kleemann A., Kutscher B., Reichert D., Bossart M., Pharmaceutical Substances, Thieme [Online], Stuttgart, (2025).
    摘要:Caron, S.; Lee, J.; Liu, Y.; Nguyen, T. N.; Piper, J. L.; Vicini, A. C., Science of Synthesis: Modern Strategies in Organofluorine Chemistry, (2025) 2.
    参考文献:10.1177/03331024211042385
    摘要:Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2021 Sep 14;42(1):3–11. doi: 10.1177/03331024211042385.
    参考文献:10.1186/s10194-021-01360-1
    摘要:Smith TR, Spierings ELH, Cady R, Hirman J, Ettrup A, Shen V. Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies. The Journal of Headache and Pain. 2021 Nov 25;22(1):143. doi: 10.1186/s10194-021-01360-1.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知